CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial

  • April 13, 2026

  • 2 min

Share

  • 1

    CRISPR therapy renizgamglogene autogedtemcel effectively raised fetal hemoglobin in patients with severe sickle cell disease.

  • 2

    In a phase 1-2 study, total hemoglobin increased from 9.8 g/dL to 13.8 g/dL within six months after treatment.

  • 3

    Fetal hemoglobin levels rose significantly from 2.5% to 48.1%, with F-cell levels exceeding 99% by month six.

  • 4

    Twenty-seven out of 28 patients experienced no severe vaso-occlusive events post-infusion, indicating clinical effectiveness.

  • 5

    The therapy demonstrated robust engraftment, with neutrophil and platelet recovery occurring within 23 and 25 days, respectively.

Original Source(s)

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

  • April 13, 2026

Related Content

Organ Preservation in Rectal Adenocarcinoma—A Growing Practice With Promise and Pitfalls

Can Immunopeptidomics Redefine Cancer Immunotherapy Development?

Immunopeptidomics is helping researchers identify tumor-presented antigens that could inform the development of targeted cell therapies and personalized cancer vaccines

Roswell Park is a Center of Excellence for Rectal Cancer Surgery

Roswell Park Comprehensive Cancer Center is a nationally accredited and certified Center of Excellence for colorectal cancer surgery due to the high volume of procedures completed annually for patients with colon and rectal cancer.

  • October 27, 2026

  • 2 min